Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Know Labs Inc. (KNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/16/2025: KNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $40
1 Year Target Price $40
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -85.09% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 822.26M USD | Price to earnings Ratio - | 1Y Target Price 40 |
Price to earnings Ratio - | 1Y Target Price 40 | ||
Volume (30-day avg) 1 | Beta 1.76 | 52 Weeks Range 0.33 - 11.06 | Updated Date 10/17/2025 |
52 Weeks Range 0.33 - 11.06 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -363.88% | Return on Equity (TTM) -1867.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 487118232 | Price to Sales(TTM) 15.57 |
Enterprise Value 487118232 | Price to Sales(TTM) 15.57 | ||
Enterprise Value to Revenue 17.32 | Enterprise Value to EBITDA -3.51 | Shares Outstanding 384233984 | Shares Floating 7190007 |
Shares Outstanding 384233984 | Shares Floating 7190007 | ||
Percent Insiders 3.78 | Percent Institutions 0.08 |
Upturn AI SWOT
Know Labs Inc.
Company Overview
History and Background
Know Labs, Inc. was founded to develop and commercialize its Bio-Raman spectroscopy technology, initially targeting non-invasive glucose monitoring. Their focus is on using light to analyze blood sugar levels without pricking the skin.
Core Business Areas
- Non-Invasive Glucose Monitoring: Developing and commercializing a non-invasive glucose monitoring device using Bio-Raman spectroscopy.
Leadership and Structure
Ron Erickson is the Chairman. The company has a management team focused on engineering, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- KnowU: A non-invasive glucose monitor utilizing Bio-Raman spectroscopy. Market share is currently 0% as the product is not yet commercially available. Competitors in glucose monitoring include Dexcom (DXCM), Abbott (ABT), and Medtronic (MDT), which all use invasive CGMs. This device is attempting to create a brand new approach to glucose monitoring.
Market Dynamics
Industry Overview
The glucose monitoring market is dominated by continuous glucose monitors (CGMs) and blood glucose meters (BGMs), both requiring invasive methods. There is significant demand for accurate and non-invasive solutions.
Positioning
Know Labs is attempting to disrupt the glucose monitoring market with its non-invasive Bio-Raman spectroscopy technology, targeting users who prefer non-invasive solutions.
Total Addressable Market (TAM)
The global glucose monitoring market is estimated to be in the tens of billions of dollars annually. Know Labs is positioned to capture a share of this market by providing a non-invasive alternative, if they can achieve both accuracy and cost effectiveness.
Upturn SWOT Analysis
Strengths
- Non-invasive technology
- Potential to disrupt existing glucose monitoring market
- Strong intellectual property portfolio
Weaknesses
- Technology not yet commercially proven
- Requires FDA approval
- Limited operating history and revenue
- Significant capital requirements
Opportunities
- Partnerships with diabetes management companies
- Expanding application of Bio-Raman spectroscopy to other biomarkers
- Growing demand for non-invasive health monitoring
Threats
- Competition from established glucose monitoring companies
- Failure to obtain FDA approval
- Technological challenges in achieving accuracy and reliability
- Potential for alternative non-invasive technologies to emerge
Competitors and Market Share
Key Competitors
- DXCM
- ABT
- MDT
Competitive Landscape
Know Labs is at a significant disadvantage compared to established players like Dexcom, Abbott and Medtronic, all of whom have substantial resources, established market presence, and regulatory expertise. Know Labs' success hinges on the successful and widespread adoption of its non-invasive technology.
Growth Trajectory and Initiatives
Historical Growth: There has been little historical growth, as the company is still in the development stage.
Future Projections: Future growth is dependent on obtaining FDA approval and successfully commercializing its glucose monitoring technology. Analyst estimates are not readily available due to the speculative nature of the company.
Recent Initiatives: Recent initiatives include ongoing clinical trials, product development efforts, and securing patents for its Bio-Raman spectroscopy technology.
Summary
Know Labs is a speculative early-stage company developing non-invasive glucose monitoring technology. They need to finish development and achieve regulatory approval to compete. The company is highly risky due to its dependence on a single technology. While the potential market is large, the company must demonstrate its product's effectiveness and cost efficiency to become a viable market participant.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Industry Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and subject to change. Investing in Know Labs involves significant risks, including the potential loss of investment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Know Labs Inc.
Exchange NYSE MKT | Headquaters Seattle, WA, United States | ||
IPO Launch date 2022-09-16 | CEO - | ||
Sector Technology | Industry Scientific & Technical Instruments | Full time employees 6 | Website https://www.knowlabs.co |
Full time employees 6 | Website https://www.knowlabs.co | ||
Know Labs, Inc., together with its subsidiaries, focuses on the development and commercialization of proprietary sensor technology by radio and microwave spectroscopy in the United States. The company involved in the identifying and measuring any material or analyte using electromagnetic energy to detect, record, identify, and measure the signature of said materials or analytes. The company was formerly known as Visualant, Incorporated and changed its name to Know Labs, Inc. in May 2018. Know Labs, Inc. was incorporated in 1998 and is based in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.